The company quietly untangling specialty pharmacy's data mess - so more patients actually start and stay on therapy.
Claritas Rx, South San Francisco, California. Fifteen years spent on a problem most of biopharma tolerates: the scattered, half-legible data trail behind every specialty prescription.
About 31% of patients never fill their prescription. Not because the medicine fails them - because the path to getting it is a maze of prior authorizations, coverage denials, and complex onboarding. Claritas Rx built its entire business at that gap.
Claritas Rx is a health-technology company based in South San Francisco, California, that integrates and analyzes the fragmented data behind specialty and rare-disease drugs. Specialty medicines - the high-cost, high-touch therapies for conditions like cancer, immune disorders, and rare genetic diseases - move through a tangle of specialty pharmacies, hubs, distributors, and payers. Each leaves behind its own slice of data, in its own format, on its own schedule. For the manufacturers who make these drugs, the result is a blind spot: they often cannot see what happens to their product after it ships, or which patients are quietly falling off therapy.
Claritas Rx exists to close that blind spot. It pulls those disparate sources into a single, validated view of the patient journey, then layers analytics and AI on top so commercial, market-access, and patient-services teams can act on what they see. The company frames its work in plainly human terms: its stated mission is to ensure patients with chronic, life-threatening diseases receive the support that lets them get the greatest benefit from their therapy.
The core work is deceptively unglamorous: data integration and validation. Specialty pharmacies report fills. Hubs track enrollment and benefits investigations. Distributors log shipments. Manufacturers hold their own commercial data. Claritas Rx aggregates all of it, reconciles it - matching protected health information across sources with 95%+ accuracy - and turns it into a trustworthy foundation. Only then does the analysis become meaningful.
The customers are biopharmaceutical manufacturers, and within them the commercial, market-access, patient-services, and field-access teams responsible for specialty and rare-disease brands. These are products where a single patient can represent enormous clinical stakes and, for rare diseases, a meaningful share of the entire patient population. The platform today spans more than 20 rare and specialty therapeutic areas, from oncology and immunology to cell and gene therapy.
Three, mainly. First, visibility - giving manufacturers a real-time, comprehensive picture of how a drug is actually performing in the market. Second, access - surfacing where prior authorizations, denials, and onboarding friction stall a patient before their first fill. Third, coordination - flagging which patients are at risk of dropping off so a care team can intervene before it happens rather than after. In complex cases, the company reports a 20% increase in first-fill rates and a 17% rise in refills where its tools are applied.
Reported improvements in complex specialty cases where the Ascend platform and Patient Watchtower are applied.
"Approximately 31% of patients never fill their prescriptions due to access barriers. Claritas Rx exists to remove those obstacles."
Ascend is Claritas Rx's AI-powered data management and analytics platform. Around it sits a suite of modules that carry a brand from raw data to coordinated patient care.
Automates and integrates channel, commercial, and clinical data into a real-time, comprehensive view of drug performance and patient adherence.
Aggregates and validates disparate specialty pharmacy, hub, and distributor data into a single trusted foundation.
Analytics on patient access, prior authorizations, coverage, and the barriers that stop patients from starting therapy.
The first care coordination platform built for specialty and rare disease brands - uniting patient-journey analytics with case coordination and AI/ML risk prediction.
A CRM layer supporting patient services and field access teams across channels.
Benchmarks brand and channel performance against comparable specialty products.
Biopharma analytics is not an empty field. Large data houses like IQVIA and Symphony Health, newer entrants like Komodo Health, and manufacturers' own internal data teams all compete for the same commercial-analytics budgets. Claritas Rx's answer has been focus rather than breadth. Instead of being a general-purpose analytics vendor, it went deep on one hard problem - patient-level specialty and rare-disease data - and became the firm manufacturers call when the underlying data is a mess.
That focus shows up in the product decisions. Patient Watchtower is positioned not as another dashboard but as a care-coordination layer purpose-built for the small, high-stakes patient populations of rare disease. Its AI is aimed at a specific, testable job: predict which patient is about to fall off therapy, accurately enough that a care team can act on it. And all of it operates inside the compliance perimeter that healthcare demands - HIPAA, HITECH, GDPR, and SOC 2 - while still hitting high match accuracy.
Claritas Rx is a B2B company selling to manufacturers through a mix of platform subscriptions and data-integration and analytics services. It has raised roughly $19 million to date, including a seed round in 2017 and a $13.6 million Series A in 2021 led by growth-equity investor Questa Capital, with Kiplin Capital also among its backers.
The domain knowledge is the moat. Founder and CEO Mike Fitzgibbons spent years at Genentech before starting the company in 2012, and the team has spent 15 years steeped in the specifics of specialty channels. That expertise has drawn outside recognition: Fitzgibbons has been named a Top Healthcare Technology CEO by The Healthcare Technology Report, and CTO Bhupesh Bajaj was named to the PM360 ELITE 100 list.
Mike Fitzgibbons leaves Genentech to fix biopharma's specialty data blind spot.
The company builds its data management and analytics platform for specialty drug performance and adherence.
Raises roughly $997K to grow the platform and team.
Questa Capital leads a growth-equity investment to accelerate product and market expansion.
Introduces its care-coordination platform for specialty and rare disease brands; named NASP Partner of the Year.
Refreshes its brand identity to mark fifteen years of specialty pharmacy data work.
Named Strategic Channel Partner of the Year by the National Association of Specialty Pharmacy in 2025.
Patient Watchtower recognized on PM360 Magazine's Best Innovations of 2025 list.
Named to the Inc. 5000 fastest-growing companies list and Inc. 2025 Best Workplaces.
CEO named a Top Healthcare Technology CEO; CTO named to the PM360 ELITE 100 list.
Claritas Rx describes a values set built around Trust and Transparency, a Customer-Centric approach, Respectful Conflict, Feedback integration, and continuous Teaching and Learning - a culture that earned it a place on the Inc. 2025 Best Workplaces list. For a company of roughly 130 people working on data most of the industry finds tedious, that emphasis on learning and candor is the connective tissue.
It integrates and analyzes fragmented specialty pharmacy, channel, and clinical data so biopharmaceutical manufacturers can understand how their specialty and rare-disease products perform and where patients hit access barriers.
Mike Fitzgibbons founded the company in 2012 after years at Genentech. He is its CEO.
Ascend is Claritas Rx's AI-powered data management and analytics platform that unifies disparate data sources into a real-time view of drug performance and patient adherence.
Launched in 2025, Patient Watchtower is a care coordination platform for specialty and rare disease brands that uses AI/ML to predict patient risk with up to 95% accuracy and drive timely interventions.
About $19.1 million total, including a roughly $997K seed round in 2017 and a $13.6 million Series A led by Questa Capital in 2021.
Profile compiled from public sources including the company website, press releases, and startup databases. Figures such as funding, revenue, and employee count are approximate and drawn from third-party reporting. Details believed accurate as of July 2026.